<DOC>
	<DOCNO>NCT00630552</DOCNO>
	<brief_summary>This multi-center , 2-part study AMG 655 , AMG 479 AMG 655-placebo plus gemcitabine first-line treatment subject metastatic pancreatic cancer . Part 1 open-label , dose-escalation phase 1b segment determine safety , tolerability maximum tolerate dose AMG 655 combination gemcitabine . Enrollment part 1 study complete . Part 2 randomized , placebo-controlled phase 2 segment estimate efficacy assess 6 month survival AMG 655 , AMG 479 , AMG 655-placebo combination gemcitabine . The phase 2 segment commence dose selection part 1 . In part 2 , subject randomize 1:1:1 AMG 655 , AMG 479 , placebo combination gemcitabine .</brief_summary>
	<brief_title>QUILT-2.019 : A Study AMG 655 AMG 479 Combination With Gemcitabine Treatment Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Untreated metastatic adenocarcinoma pancreas ( AJCC Stage IV ) Subjects unresectable pancreatic cancer surgery eligible fully recover great 30 day elapse since surgery . Subjects history pancreatoduodenectomy eligible provide radiographically documented disease recurrence . Men woman ≥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) score 0 1 Adequate hematologic , hepatic , renal coagulation function Amylase lipase ≤ 2.0 x ULN Adequately control type 1 2 diabetic subject Islet cell , acinar cell carcinoma , nonadenocarcinoma ( eg , lymphoma , sarcoma , etc ) , adenocarcinoma originate biliary tree cystadenocarcinoma Known central nervous system metastasis Uncontrolled cardiac disease comorbid disease would increase risk toxicity Adjuvant chemotherapy chemoradiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AMG 479</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>TR-2</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>AMG 655</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Adenocarcinoma Pancreas</keyword>
	<keyword>Metastatic Pancreatic Cancer</keyword>
</DOC>